Chimeric Therapeutics Ltd News

Chimeric Therapeutics Ltd: Investor webinar

Oct 24 13:11

Chimeric Therapeutics Ltd: Dose finding complete in ADVENT-AML Phase 1b clinical trial

Oct 24 06:55

Chimeric Therapeutics Ltd: Reinstatement to Official Quotation

Oct 21 16:01

Chimeric Therapeutics Ltd: ESG Report

Oct 21 12:12

Chimeric Therapeutics Ltd: Corporate Governance Statement and Appendix 4G

Oct 21 12:12

Chimeric Therapeutics Ltd: AML patient achieves Complete Response in CHM CORE-NK trial

Oct 7 06:45

Chimeric Therapeutics Ltd: 2024 Annual Report update

Oct 4 10:05

Suspension from Quotation

Oct 1 07:33

Chimeric Therapeutics Ltd: Achieve Clinics collaboration to expand reach of CHM CDH17

Sep 25 06:25

Chimeric Therapeutics Ltd: University of Pennsylvania joins CHM CDH17 Phase 1/2 trial

Sep 11 07:38

Chimeric Therapeutics Ltd: First patient dosed in Phase 1/2 trial of CHM CDH17

Aug 28 07:57

Chimeric Therapeutics Ltd: Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete

Aug 16 07:21

Chimeric Therapeutics Ltd: Chimeric receives $1.5 M advance on FY24 R&D tax incentive

Aug 13 08:05

Chimeric Therapeutics Ltd: Chimeric partnering with Cell Therapies Australia

Aug 9 07:06

Chimeric Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jul 31 07:37

Chimeric Therapeutics Ltd: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial

Jul 22 08:12

Chimeric Therapeutics Ltd: Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

Jun 5 07:11

Chimeric Therapeutics Ltd: Final Director's Interest Notice

May 30 15:55

Chimeric Therapeutics Ltd: Chimeric opens CHM CDH17 Phase 1/2 trial

May 22 08:14

Chimeric Therapeutics Ltd: CHM CDH17 Phase 1/2 clinical trial approved for initiation

May 20 07:00